HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $77,050,241 | -13.7% | 2,017,022 | -18.5% | 0.02% | -8.7% |
| Q2 2023 | $89,314,551 | -33.0% | 2,476,145 | -29.1% | 0.02% | -37.8% |
| Q1 2023 | $133,328,049 | -61.0% | 3,491,177 | -41.9% | 0.04% | -63.0% |
| Q4 2022 | $341,710,162 | +53.3% | 6,005,451 | +6.5% | 0.10% | +38.9% |
| Q3 2022 | $222,946,000 | -9.0% | 5,638,497 | +1.2% | 0.07% | -2.7% |
| Q2 2022 | $245,110,000 | +15.5% | 5,570,695 | +4.7% | 0.07% | +37.0% |
| Q1 2022 | $212,207,000 | -4.2% | 5,321,123 | -3.4% | 0.05% | +1.9% |
| Q4 2021 | $221,406,000 | +2.1% | 5,506,233 | +3.3% | 0.05% | -3.6% |
| Q3 2021 | $216,799,000 | -15.5% | 5,329,345 | -5.7% | 0.06% | -12.7% |
| Q2 2021 | $256,639,000 | +11.5% | 5,651,622 | +2.4% | 0.06% | +3.3% |
| Q1 2021 | $230,201,000 | +1.1% | 5,521,734 | +3.5% | 0.06% | -7.6% |
| Q4 2020 | $227,756,000 | +104.1% | 5,332,608 | +25.6% | 0.07% | +73.7% |
| Q3 2020 | $111,577,000 | +13.0% | 4,245,697 | +15.3% | 0.04% | +8.6% |
| Q2 2020 | $98,721,000 | +49.2% | 3,682,281 | +0.1% | 0.04% | +25.0% |
| Q1 2020 | $66,166,000 | -21.1% | 3,677,932 | -22.2% | 0.03% | +7.7% |
| Q4 2019 | $83,841,000 | +2.6% | 4,728,817 | -10.2% | 0.03% | +23.8% |
| Q3 2019 | $81,688,000 | -11.7% | 5,266,794 | -2.2% | 0.02% | -12.5% |
| Q2 2019 | $92,555,000 | +36.7% | 5,387,409 | +28.2% | 0.02% | +4.3% |
| Q1 2019 | $67,683,000 | +9.8% | 4,203,858 | -0.2% | 0.02% | -4.2% |
| Q4 2018 | $61,652,000 | -18.8% | 4,214,114 | +0.8% | 0.02% | 0.0% |
| Q3 2018 | $75,941,000 | +10.7% | 4,179,453 | +2.8% | 0.02% | +4.3% |
| Q2 2018 | $68,593,000 | -17.2% | 4,065,916 | -3.8% | 0.02% | -25.8% |
| Q1 2018 | $82,816,000 | -3.6% | 4,227,482 | -0.3% | 0.03% | 0.0% |
| Q4 2017 | $85,914,000 | +11.7% | 4,240,612 | -4.2% | 0.03% | +10.7% |
| Q3 2017 | $76,883,000 | +35.0% | 4,426,226 | -0.4% | 0.03% | +55.6% |
| Q2 2017 | $56,950,000 | -2.0% | 4,442,300 | -0.9% | 0.02% | -5.3% |
| Q1 2017 | $58,121,000 | +151.6% | 4,484,611 | +91.8% | 0.02% | +137.5% |
| Q4 2016 | $23,097,000 | +5.6% | 2,337,739 | +29.1% | 0.01% | 0.0% |
| Q3 2016 | $21,876,000 | +41.3% | 1,810,904 | +1.0% | 0.01% | +33.3% |
| Q2 2016 | $15,479,000 | -40.0% | 1,793,534 | -34.1% | 0.01% | -40.0% |
| Q1 2016 | $25,791,000 | -37.8% | 2,723,463 | +13.9% | 0.01% | -41.2% |
| Q4 2015 | $41,444,000 | +25.4% | 2,391,473 | -2.9% | 0.02% | +21.4% |
| Q3 2015 | $33,062,000 | +32.8% | 2,461,836 | +123.3% | 0.01% | +40.0% |
| Q2 2015 | $24,889,000 | +27250.5% | 1,102,276 | +18149.6% | 0.01% | – |
| Q4 2013 | $91,000 | – | 6,040 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |